Abstract
Recent results from high-throughput and other screening approaches reveal that small molecules can directly interact with recombinant full-length tau monomers and fibrillar tau aggregates in three distinct modes. First, in the high concentration regime ( > 10 micromolar), certain anionic molecules such as Congo red efficiently promote tau filament formation through a nucleation-elongation mechanism involving a dimeric nucleus and monomer-mediated elongation. These compounds are useful for modeling tau aggregation in vitro and in biological models. Second, in the low concentration regime ( < 1 micromolar), other ligands, including cyanine dyes, display aggregation antagonist activity. Compounds that can prevent or reverse fibrillization are candidate modifiers of disease pathology. Finally, certain compounds bind mature tau fibrils with varying affinities at multiple binding sites without modulating the aggregation reaction. For some ligands, > 10-fold selectivity for tau aggregates relative to filaments composed of beta-amyloid or alpha-synuclein can be demonstrated at the level of binding affinity. Together these observations suggest that small-molecules have utility for interrogating the tau aggregation pathway, for inhibiting neuritic lesion formation, and for selective pre-mortem detection of neurofibrillary lesions through whole brain imaging.
Keywords: Alzheimer's disease, frontotemporal lobar degeneration, tau, neurofibrillary tangle, paired helical filaments, aggregation
Current Alzheimer Research
Title: Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Volume: 6 Issue: 5
Author(s): Edward Chang, Nicolette S. Honson, Bhaswati Bandyopadhyay, Kristen E. Funk, Jordan R. Jensen, Sohee Kim, Swati Naphade and Jeff Kuret
Affiliation:
Keywords: Alzheimer's disease, frontotemporal lobar degeneration, tau, neurofibrillary tangle, paired helical filaments, aggregation
Abstract: Recent results from high-throughput and other screening approaches reveal that small molecules can directly interact with recombinant full-length tau monomers and fibrillar tau aggregates in three distinct modes. First, in the high concentration regime ( > 10 micromolar), certain anionic molecules such as Congo red efficiently promote tau filament formation through a nucleation-elongation mechanism involving a dimeric nucleus and monomer-mediated elongation. These compounds are useful for modeling tau aggregation in vitro and in biological models. Second, in the low concentration regime ( < 1 micromolar), other ligands, including cyanine dyes, display aggregation antagonist activity. Compounds that can prevent or reverse fibrillization are candidate modifiers of disease pathology. Finally, certain compounds bind mature tau fibrils with varying affinities at multiple binding sites without modulating the aggregation reaction. For some ligands, > 10-fold selectivity for tau aggregates relative to filaments composed of beta-amyloid or alpha-synuclein can be demonstrated at the level of binding affinity. Together these observations suggest that small-molecules have utility for interrogating the tau aggregation pathway, for inhibiting neuritic lesion formation, and for selective pre-mortem detection of neurofibrillary lesions through whole brain imaging.
Export Options
About this article
Cite this article as:
Chang Edward, Honson S. Nicolette, Bandyopadhyay Bhaswati, Funk E. Kristen, Jensen R. Jordan, Kim Sohee, Naphade Swati and Kuret Jeff, Modulation and Detection of Tau Aggregation with Small-Molecule Ligands, Current Alzheimer Research 2009; 6 (5) . https://dx.doi.org/10.2174/156720509789207976
DOI https://dx.doi.org/10.2174/156720509789207976 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Human Umbilical Cord Stem Cell Xenografts Improve Cognitive Decline and Reduce the Amyloid Burden in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science The Role of Genes (and Environmental Stress) in Depression: An Update
Current Psychiatry Reviews The Use of Flavonoids in Central Nervous System Disorders
Current Medicinal Chemistry From Traditional European Medicine to Discovery of New Drug Candidates for the Treatment of Dementia and Alzheimer's Disease: Acetylcholinesterase Inhibitors
Current Medicinal Chemistry [<sup>18</sup>F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, <i>In Silico, In vitro</i> and <i>In vivo</i> Evaluations
Current Radiopharmaceuticals Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry The Astrogenic Balance in the Aging Brain
Current Neuropharmacology Recent Advances in the Development of Pyrimidine-based CNS Agents
Current Drug Discovery Technologies Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Editorial - The As and Ms of Alzheimers Disease
Current Alzheimer Research